

KEYMEULEN Bart

Date, Place of Birth February 14, 1961, Aalst - Belgium
Nationality Belgian

Address Diabetes Research Center
 Vrije Universiteit Brussel
 Laarbeeklaan 103
 B-1090 Brussel, Belgium
 Tel. 32-2-4774541
 Fax. 32-2-4774545
 E-mail: Bart.Keymeulen@vub.be

 Diabeteskliniek
 UZ Brussel
 Laarbeeklaan 101
 B-1090 Brussel, Belgium
 Tel. 32-2-477 78 76
 Fax. 32-2-477 78 03
 E-mail: Bart.Keymeulen@uzbrussel.be

Short Biography

Bart Keymeulen, MD PhD, is professor of medicine at Brussels Free University (VUB), senior clinical investigator of Belgian scientific research fund-Flanders (Belgium) and head of the diabetes clinic with integrated research unit at UZ Brussel. After obtaining a PhD in medical sciences in Diabetes Research Center (prof. D Pipeleers) at Brussels Free University (VUB), he became head of the clinical trial section of the *Center for Beta Cell Therapy in Diabetes*, a European network of clinical and research departments, associated to reference centers and bioindustry partners.

Major accomplishments are a prevention trial in recent-onset type 1 diabetic patients (B. Keymeulen et. al. NEJM 2005, Blood 2010, Diabetologia 2010) and an islet beta cell transplantation study in non-uremic patients (B. Keymeulen et. al. PNAS USA 2006) that was based on earlier observations in type 1 diabetic patients with a prior kidney graft (B. Keymeulen et. al. Diabetologia 1997).

Bart Keymeulen is author of 124 publications in PubMed, mostly in the field of type 1 diabetes.

Education

Medical studies at Brussels Free University-VUB

- 1984-85 4^o clinical: "Summa Cum Laude"
Study orientation: Medical Research
Thesis: "In vivo visualization of the Pancreatic β cells"
(promoter D. Pipeleers)
Brussels Free University - VUB
- 1985 Medical Doctor
- 1985-87 Master in Hospital Sciences at Brussels Free University-VUB
"Summa Cum Laude"
- 1987 Master in Hospital Sciences
- 1985-91 Training in Internal Medicine at Academic Hospital Brussels Free
University-VUB
"Summa Cum Laude"
- 1991 Specialist in Internal Medicine
- 1994 PhD in Medical Sciences (Geaggregeerde vr het Hoger Onderwijs) at
Brussels Free University-VUB
"unanimity"
Thesis "Metabolic effects of pancreatic β cell transplantation in
streptozotocin-diabetic rats". (promoter D. Pipeleers)
Public lecture "Prevention of Diabetes"
- 1998 Specialist in Endocrinology and Diabetology (created in Belgium in
1998)

Good Clinical Practice Training

- 1998 Certificate Good Clinical Practice for Investigators, Brookwood
International Academy of Healthcare Research
- 2012 Good Clinical Practice (GCP) and Best Practices when Managing Clinical
Trials - Janssen Cilag; Johnson & Johnson
Investigator Safety Training - Janssen Cilag; Johnson & Johnson
- 2013 Principles of ICH Good Clinical Practice Training Course - Boehringer
7-06-2013
- 2014 Good Clinical Practice training meeting "Minimum Criteria for ICH E6
GCP Investigator Site Personnel Training", identified by TransCelerate
BioPharma, Inc., entitled 27-02-2014
- 2015 Good Clinical Practice training meeting "Minimum Criteria for ICH E6
GCP Investigator Site Personnel Training", identified by TransCelerate
BioPharma, Inc., entitled 14-08-2015
- 2017 Good Clinical Practice: A Review of ICH E6, Revision 2 Changes for Site
Personnel Working on Clinical Research Studies, entitled 01-10-2017

Position in Belgian Scientific Research Fund-Flanders, Belgium

1989 - 1993 Research Assistant, National Fund Scientific Research, Belgium
1993 - 1995 Postdoctoral Researcher, National Fund Scientific Research, Belgium
2001 - 2016 Senior Clinical Investigator of Belgian Scientific Research Fund-Flanders, Belgium

Position in Diabetes Research Center

1984 - 1985 Student
1989 - 1993 PhD student
1993 - 1994 Postdoctoral Researcher
1994 - 2001 Trial team leader "β Cell Transplant", multicenter program on islet cell transplantation in diabetes
2001 - 2017 Head Clinical Trials of Center for Beta Cell therapy (Human pancreatic beta cell transplantation, pharmacological interventions in pre-type 1 diabetes and in recent onset Type 1 diabetes)
2017 - today Head Research Cluster Diabetes

Position in Faculty

1989 - 1997 Assistant professor of medicine, Brussels Free University - VUB
1997 - 2002 Professor of medicine ("Docent"), Brussels Free University - VUB
2002 - 2009 Professor of medicine ("Hoofddocent"), Brussels Free University - VUB
2009 - 2012 Professor of medicine ("Hoogleraar"), Brussels Free University - VUB
2013 - 2016 Professor of medicine ("Buitengewoon Hoogleraar"), Brussels Free University - VUB
2016 - today Full professor of medicine ("Gewoon Hoogleraar"), Brussels Free University - VUB

Position in University Hospital Brussels

1985 - 91 Resident Department of Internal Medicine/Endocrinology
1991 - 95 Clinical Staff Member Dept. of Endocrinology
1995 - 97 Associate Head Dept. of Endocrinology
1997 - 2009 Head Diabetic Unit, Dept. of Endocrinology
2009 - today Head ("Diensthoofd") Diabetes Clinic
2012 - today Head Clinical Trial Center

Honors and awards

1989 Novo Nordisk Award for Diabetology
1999 Honorary member of the Georgian Society of Internal Medicine
2006 Co-author Bial Merit Award in Medical Sciences
2006 Honorary Member of the International Society of Internal Medicine
2006 Winner of the prize of the best Belgian article in internal medicine of the year 2005. (Belgische vereniging voor interne geneeskunde)
2007 Co-author Bial Merit Award in Medical Sciences of the year 2006. Biological Platform for Beta Cell Therapy in Diabetes
2007 Prize of Belgian Royal Academy of Medicine (Prijs Dr. Luc Broeckaert en Mevr. Annie Depreuw)

Research Area

Development of Beta Cell Therapy in Human Type 1 Diabetes
Publication List: see PubMed under Keymeulen-B

Scientific publications

A. Scientific Reviews

1. Bossuyt X, Keymeulen B, Pen J, Gorus F, Weets I. Carbohydraatmetabolisme. In: Wegwijs in laboratoriumdiagnose, Acco 2016 p.255 - 270
2. Gillard P, Lannoo M, Keymeulen B, Mathieu C. Traitement du Diabète par la Greffe d'îlots. In Actualités Néphrologique Jean Hamburger. Lesavre P, Drüeke T, Legendre C., Niaudet P Eds. Flammarion Médecine-Sciences, Hôpital Necker, 2004 p. 159-165
3. Pipeleers D, Keymeulen B, Korbitt G. Islet transplantation. In: Diabetes Annual 8, Marshall S and Home P (eds.), Elsevier Science Publishers 1994; 8: 299-330

B. Scientific Articles in International peer-reviewed Medical Journals

1. Roels S, Costa OR, Tersey SA, Stangé G, De Smet D, Balti EV, Gillard P, Keymeulen B, Ling Z, Pipeleers DG, Gorus FK, Mirmira RG, Martens GA. Combined Analysis of GAD65, miR-375 and Unmethylated Insulin DNA Following Islet Transplantation in T1D Patients. **J Clin Endocrinol Metab.** 2019 Feb. 1;104(2):451-460
2. Vlasakakis G, Napolitano A, Barnard R, Brown K, Bullman J, Inman D, Keymeulen B, Lanham D, Leirens Q, MacDonald A, Mezzalana E, Page K, Patel M, Savage CO, Zamuner S, van Maurik A. Target engagement and cellular fate of oteelixumab; a repeat dose escalation study of an anti-CD3 ϵ mAb in New-Onset Type 1 Diabetes Mellitus Patients. **J Clin Pharmacol.** 2018 Dec 19. Epub ahead of print
3. De Mesmaeker I, Robert T, Suenens KG, Stangé GM, Van Hulle F, Ling Z, Tomme P, Jacobs-Tulleneers-Thevissen D, Keymeulen B, Pipeleers DG. Increase Functional β -Cell Mass in Subcutaneous Alginate Capsules With Porcine Prenatal Islet Cells but Loss With Human Adult Islet Cells. **Diabetes.** 2018 Dec; 67(12):2640-2649
4. De Jaeger M, Goudman L, Van Schuerbeek P, De Mey J, Keymeulen B, Brouns R, Moens M. Cerebral Biochemical effect fo pregabalin in patients with painful diabetic neuropathy: a randomized controlled trial. **Diabetes technology & therapeutics.** 2018 Aug;9, 4, 1591-1604
5. Balke E M, Balti E V, Van der Auwera B, Weets I, Costa O, Demeester S, Abrams P, Casteels K, Coeckelberghs M, Tenoutasse S, Keymeulen B, Pipeleers D G, Gorus F K, Belgian Diabetes Registry. Accelerated progression to type 1 diabetes in the presence of HLA-A*24 and -B*18 is restricted to multiple-islet autoantibody-positive individuals with distinct HLA-DQ- and autoantibody risk profiles. **Diabetes Care.** 2018, May; 41,5; p. 1076-1083
6. Balke E, Demeester S, Lee D, Gillard P, Hilbrands R, Van de Veld U, Van der Auwera B, Ling Z, Roep B, Pipeleers D G, Keymeulen B, Gorus F K. SLC30A8 polymorphism and BMI complement HLA-A*24 as risk factors for poor graft function in islet allograft recipients. **Diabetologia** 2018 April; 61, 7 p.1623 - 1632
7. Pen JJ, Khorosheva G, Van de Velde U, Debroye C, Huyghebaert A, Rottiers R, Keymeulen B. Zùsto: A new sweetening agent with low glycemic index. **Clin Nutr ESPEN.** 2018 Feb;23:103-106

8. Rickels MR, Stock PG, de Koning EJP, Piemonti L, Pratschke J, Alejandro R, Bellin MD, Berney T, Choudhary P, Johnson PR, Kandaswamy R, Kay TWH, Keymeulen B, Kudva YC, Latres E, Langer RM, Lehmann R, Ludwig B, Markmann JF, Marinac M, Odorico JS, Pattou F, Senior PA, Shaw JAM, Vantyghem MC, White S. Defining Outcomes for β -Cell Replacement Therapy in the Treatment of Diabetes: a Consensus Report on the Igl's Criteria from the IPITA/EPITA Opinion Leaders Workshop. **Transpl Int.** 2018 Feb 17. (IF: 3.2) (1 ISI-citation)
9. Charleer S, Mathieu C, Nobels F, De Block C, Radermecker RP, Hermans MP, Taes Y, Vercammen C, T'Sjoen G, Crenier L, Fieuws S, Keymeulen B, Gillard P; RESCUE trial investigators. Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions and Quality of Life: A Real-World Study. **J Clin Endocrinol Metab.** 2018 Jan 12, 103, 3, p. 1224-1232 (IF: 5.8) (5 ISI-citations)
10. Hae Lee D, Keymeulen B, Hilbrands R, Ling Z, Van de Velde U, Jacobs-Tulleneers-Thevissen D, Maleux G, Lapauw B, Crenier L, De Block C, Mathieu C, Pipeleers D, Gillard P. Age and early graft function relate with risk-benefit ratio of allogenic islet transplantation under Anti-thymocyte globulin -Mycophenolate mofetil - Tacrolimus immune suppression. **Transplantation.** 2017;100:2218 (IF: 4.0) (1 ISI-citation)
11. Gorus FK, Balti EV, Messaaoui A, Demeester S, Van Dalem A, Costa O, Dorchy H, Mathieu C, Van Gaal L, Keymeulen B, Pipeleers DG, Weets I; Belgian Diabetes Registry. Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes. **Diabetes Care.** 2017 Aug;40(8):1065-1072 (IF 13.4) (7 ISI-citations)
12. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondy N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. **N Engl J Med.** 2017 Aug 17;377(7):644-657. (IF: 79.3) (14 ISI-citations)
13. Van Dalem A, Demeester S, Balti EV, Keymeulen B, Gillard P, Lapauw B, De Block C, Abrams P, Weber E, Vermeulen I, De Pauw P, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry. Correction: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio. **PLoS One.** 2017 Jun 1;12(6). (IF: 2.8)
14. Van Dalem A, Demeester S, Balti EV, Keymeulen B, Gillard P, Lapauw B, De Block C, Abrams P, Weber E, Vermeulen I, De Pauw P, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry. Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio. **PLoS One.** 2016 Dec 1;11(12). Erratum in: PLoS One. 2017 Jun 1;12 (6) (IF: 2.8) (1 ISI-citation)
15. van der Torren CR, Suwandi JS, Lee D, van 't Wout ET, Duinkerken G, Swings G, Mulder A, Claas FH, Ling Z, Gillard P, Keymeulen B, Veld PI, Roep BO. Identification of donor origin and condition of transplanted islets in situ in the liver of a type 1 diabetic recipient. **Cell Transplant.** 2017; 26: 1-9 (IF: 2.9)
16. Pipeleers D, Keymeulen B. Boost for Alginate Encapsulation in Beta Cell Transplantation. **Trends Endocrinol Metab.** 2016 May;27(5):247-8. (IF: 10.8) (6 ISI-citations)
17. Demeester S, Balke E M, Van der Auwera B J, Gillard P, Hilbrands R, Lee D, Van de Velde U, Ling Z, Roep B O, Pipeleers D G, Gorus F K, Keymeulen B. HLA-A*24 Carries Status and Autoantibody Surges Posttransplantation Associate With Poor Functional Outcome in Recipients of an Islet Allograft. **Diabetes Care.** 2016; 39, 6: 1060-1064 (IF: 13.4)

18. MacDonald A, Ambery P, Donaldson J, Hicks K, [Keymeulen B](#), Parkin J. Subcutaneous Administration of Otelixizumab is Limited by Injection Site Reactions: Results of an Exploratory Study in Type 1 Diabetes Mellitus Patients. **Exp Clin Endocrinol Diabetes**. 2016 May;124(5):288-93 (IF: 1.6)
19. Crenier L, Lytrivi M, Van Dalem A, [Keymeulen B](#), Corvilain B. Glucose Complexity Estimates Insulin Resistance in Either Nondiabetic Individuals or in Type 1 Diabetes. **J Clin Endocrinol Metab**. 2016 Apr;101(4):1490-7. (IF: 5.8) (4 ISI-citations)
20. van der Torren CR, Verrijn Stuart AA, Lee D, Meerding J, van de Velde U, Pipeleers D, Gillard P, [Keymeulen B](#), de Jager W, Roep BO. 1. Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 Diabetes. **PLoS One**. 2016 Jan 11;11(1):e0146649 (IF: 2.8) (3 ISI-citations)
21. Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruyse F, Meininger G, Neal B; [CANVAS trial collaborative group](#). Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. **Diabetes Obes Metab**. 2016 Jan;18(1):82-91. (IF: 6.0) (32 ISI-citations)
22. Van Dalem A, Demeester S, Balti EV, Decochez K, Weets I, Vandemeulebroucke E, Van de Velde U, Walgraeve A, Seret N, De Block C, Ruige J, Gillard P, [Keymeulen B](#), Pipeleers DG, Gorus FK; Belgian Diabetes Registry. Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes. **Diabetologia**. 2015 Dec;58(12):2753-64. (IF: 6.0) (5 ISI-citations)
23. Choudhary P, Rickels MR, Senior PA, Vantuyghem MC, Maffi P, Kay TW, [Keymeulen B](#), Inagaki N, Saudek F, Lehmann R, Hering BJ. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. **Diabetes Care**. 2015 Jun;38(6):1016-29. (IF: 13.4) (52 ISI-citations)
24. Ling Z, De Pauw P, Jacobs-Tulleneers-Thevissen D, Mao R, Gillard P, Hampe CS, Martens GA, In't Veld P, Lernmark Å, [Keymeulen B](#), Gorus F, Pipeleers D. Plasma GAD65, a Marker for Early β -Cell Loss After Intraportal Islet Cell Transplantation in Diabetic Patients. **J Clin Endocrinol Metab**. 2015 Jun;100(6):2314-21. (IF: 5.8) (8 ISI-citations)
25. Demeester S, [Keymeulen B](#), Kaufman L, Van Dalem A, Balti EV, Van de Velde U, Goubert P, Verhaeghen K, Davidson HW, Wenzlau JM, Weets I, Pipeleers DG, Gorus FK. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual Beta-cell function in recent-onset type 1 diabetes. **Diabetes Care**. 2015 Apr;38(4):644-51. (IF: 13.4) (8 ISI-citations)
26. Balti EV, Vandemeulebroucke E, Weets I, Van De Velde U, Van Dalem A, Demeester S, Verhaeghen K, Gillard P, De Block C, Ruige J, [Keymeulen B](#), Pipeleers DG, Decochez K, Gorus FK; The Belgian Diabetes Registry. Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patients. **J Clin Endocrinol Metab**. 2015 Feb;100(2):551-60. (IF: 5.8) (4 ISI-citations)
27. Gillard P, Rustandi M, Efendi A, Lee da H, Ling Z, Hilbrands R, Kuypers D, Mathieu C, Jacobs-Tulleneers-Thevissen D, Gorus F, Pipeleers D, [Keymeulen B](#). Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. **Transplantation**. 2014 Aug 27;98(4):451-7 (IF: 4.0) (5 ISI-citations)
28. Aerden D, Lipsky BA, Denecker N, Nieboer K, [Keymeulen B](#). Gas gangrene in the diabetic foot: lessons learned from a salvaged limb. **Acta Chir Belg**. 2014 Jan-Feb;114(1):66-70 (IF: 0.4)

29. Asanghanwa M, Gorus FK, Weets I, der Auwera BV, Aminkeng F, Mbunwe E, Goubert P, Verhaeghen K, Sobngwi E, Wenzlau JM, Hutton JC, Pipeleers DG, Keymeulen B, Mbanya JC, van Schravendijk C. Clinical and biological characteristics of diabetic patients under age 40 in Cameroon: Relation to autoantibody status and comparison with Belgian patients. **Diabetes Res Clin Pract.** 2014 Jan;103(1): 97-105 (IF: 2.5) (3 ISI-citations)
30. Gorus FK1, Keymeulen B, Veld PA, Pipeleers DG . Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase. **Expert Rev Clin Immunol.** 2013 Dec;9(12):1173-83. (IF: 3.4) (15 ISI-citations)
31. Gillard P, Hilbrands R, Van de Velde U, Ling Z, Lee da H, Weets I, Gorus F, De Block C, Kaufman L, Mathieu C, Pipeleers D, Keymeulen B. Minimal functional B-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients. **Diabetes Care.** 2013 Nov;36(11):3483-8 (IF: 13.4) (11 ISI-citations)
32. Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, Van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK, The Belgian Diabetes Registry. In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18 - but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions. **Diabetologia** 2013 Sep;56(9): 1964-70 (IF: 6.0) (7 ISI-citations)
33. Jiang L, Brackeva B, Ling Z, Kramer G, Aerts JM, Schuit F, Keymeulen B, Pipeleers D, Gorus F, Martens GA. Potential of protein phosphatase inhibitor 1 as biomarker of pancreatic beta cell injury in vitro and in vivo. **Diabetes** 2013 Aug;62(8): 2683-8 (IF: 7.3) (15 ISI-citations)
34. Hilbrands R, Gillard P, Van der Torren CR, Ling Z, Verheyden S, Jacobs-Tulleneers-Thevissen D, Roep BO, Claas FHJ, Demanet C, Gorus FK, Pipeleers D, Keymeulen B. Predictive factors of allosensitization following immunosuppressant withdrawal in recipients of long-term cultured islet cell grafts. **Transplantation** 2013 Jul;96(2): 162-9 (IF: 4.0) (3 ISI-citations)
35. Jacobs-Tulleneers-Thevissen D, Chintinne M, Ling Z, Gillard P, Schoonjans L, Delvaux G, Strand BL, Gorus F, Keymeulen B, Pipeleers D. Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. **Diabetologia** 2013 Jul;56(7): 1605-14 (IF: 6.0) (79 ISI-citations)
36. Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions. **Diabetologia.** 2013 Sep;56(9):1964-70. (IF:6.0) (7 ISI-citations)
37. Aerden D, Bosmans I, Vanmierlo B, Spinael J, Keymeulen B, Van den Brande P. Skin grafting the contaminated wound bed: reassessing the role of the preoperative swab. **Journal of Wound Care** 2013 Feb; 22(2): 85-9 (IF: 1.7) (5 ISI-citations)
38. Huurman VAL, van der Torren CR, Gillard P, Hilbrands R, van der Meer-Prins EPMW, Duinkerken G, Gorus F, Claas FHJ, Keymeulen B, Roelen DL, Pipeleers DG, Roep BO. Immune responses against islet allografts during tapering of immunosuppression - a pilot study in 5 subjects. **Clin exp immunol.** 2012 Aug ; 169(2): 190-8 (IF: 3.5) (10 ISI-citations)

39. Aerden D, Vanmierlo B, Denecker N, Brasseur L, Keymeulen B, Van den Brande P. Primary closure with a filleted hallux flap after transmetatarsal amputation of the big toe for osteomyelitis in the diabetic foot: a short series of four cases. **Int J Low Extrem Wounds**. 2012; 11(2): 80-4 (IF: 1.2) (5 ISI-citations)
40. De Keyzer E, Kerkhove D, Van Camp G, De Sutter J, Achtergael W, Keymeulen B, Weytjens C. Screening for silent myocardial ischaemia in patients with type 2 diabetes mellitus: a quest to improve selection of the target screening population. **Acta Cardiol**. 2011 Dec;66(6): 715-20 (IF: 0.9) (3 ISI-citations)
41. Aerden D, Haentjens P, von Kemp K, Van den Bossche B, Staelens I, Debing E, Keymeulen B, Van den Brande P. The surgical history of the amputated limb according to the indication for revascularization: diabetic foot, acute ischaemia, aneurysmal disease, chronic arterial occlusive disease. **Acta Chir Belg**. 2011 Nov-Dec;111(6): 384-8 (IF: 1.0)
42. Alkemade GM, Hilbrands R, Vandemeulebroucke E, Pipeleers D, Waldmann H, Mathieu C, Keymeulen B, Roep BO. Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients. **Diabetes Metab Res Rev**. 2011 Nov;27(8):925-7 (IF: 3.9) (2 ISI-citations)
43. Caumo A, Maffi P, Nano R, Luzi L, Hilbrands R, Gillard P, Jacobs-Tulleneers-Thevissen D, Secchi A, Keymeulen B, Pipeleers D, Piemonti L. Comparative evaluation of simple indices of graft function after islet transplantation. **Transplantation**. 2011 Oct 15;92(7):815-21 (IF: 4.0) (19 ISI-citations)
44. Vermeulen I, Weets I, Asanghanwa M, Ruige J, Van Gaal L, Mathieu C, Keymeulen B, Lampasona V, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; The Belgian Diabetes Registry. Contribution of Antibodies Against IA-2{beta} and ZincTransporter 8 to Classification of Diabetes Diagnosed Under 40 Years of Age. **Diabetes Care**. 2011 Aug;34(8):1760-1765 (IF: 13.4) (35 ISI-citations)
45. Aerden D, Massaad D, von Kemp K, van Tussenbroek F, Debing E, Keymeulen B, Vanden Brande P. The ankle-brachial index and the diabetic foot: a troublesome marriage. **Ann Vasc Surg**. 2011 Aug;25(6):770-7. (IF: 1.4) (48 ISI-citations)
46. Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK; DIRECT Study Group. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials. **Diabetologia**. 2011 Jun;54(6):1298-303. (IF: 6.0) (22 ISI-citations)
47. Unger WW, Velthuis J, Abreu JR, Laban S, Quinten E, Kester MG, Reker Hadrup S, Bakker AH, Duinkerken G, Mulder A, Franken KL, Hilbrands R, Keymeulen B, Peakman M, Ossendorp F, Drijfhout JW, Schumacher TN, Roep BO. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. **J Autoimmun**. 2011 Nov;37(3):151-9. (IF: 7.6) (29 ISI-citations)
48. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. **N Engl J Med**. 2011 Mar 10;364(10):907-17. (IF: 79.3) (422 ISI-citations)
49. Gillard P, Keymeulen B, Mathieu C. Beta-cell transplantation in type 1 diabetic patients: a work in progress to cure. **Verh K Acad Geneesk Belg**. 2010;72(1-2):71-98.

50. Velthuis JH, Unger WW, Abreu JR, Duinkerken G, Franken K, Peakman M, Bakker AH, Reker-Hadrup S, Keymeulen B, Drijfhout JW, Schumacher TN, Roep BO. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. **Diabetes**. 2010 Jul;59(7):1721-30. (IF: 7.3) (107 ISI-citations)
51. Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C, Candon S, Waldmann H, Ziegler AG, Chatenoud L, Pipeleers D. Four-year metabolic outcome of a randomized controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. **Diabetologia**. 2010 Apr;53(4):614-23. (IF: 6.0) (183 ISI-citations) (Subject of editorial)
52. Hale G, Rebello P, Al Bakir I, Bolam E, Wiczling P, Jusko WJ, Vandemeulebroucke E, Keymeulen B, Mathieu C, Ziegler AG, Chatenoud L, Waldmann H. Pharmacokinetics and antibody responses to the CD3 antibody oteelixumab used in the treatment of type 1 diabetes. **J Clin Pharmacol**. 2010 Nov;50(11):1238-48. (IF: 2.9) (24 ISI-citations)
53. De Grijse J, Asanghanwa M, Nouthe B, Albrecher N, Goubert P, Vermeulen I, Van Der Meeren S, Decochez K, Weets I, Keymeulen B, Lampasona V, Wenzlau J, Hutton JC, Pipeleers D, Gorus FK; Belgian Diabetes Registry. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. **Diabetologia**. 2010 Mar;53(3):517-24. (IF: 6.0) (53 ISI-citations)
54. Keymeulen B, Candon S, Fafi-Kremer S, Ziegler A, Leruez-Ville M, Mathieu C, Vandemeulebroucke E, Walter M, Crenier L, Thervet E, Legendre C, Pierard D, Hale G, Waldmann H, Bach JF, Seigneurin JM, Pipeleers D, Chatenoud L. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. **Blood**. 2010 Feb 11;115(6):1145-55. (IF: 15.1) (44 ISI-citations)
55. Vandemeulebroucke E, Keymeulen B, Decochez K, Weets I, De Block C, Féry F, Van de Velde U, Vermeulen I, De Pauw P, Mathieu C, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. **Diabetologia**. 2010 Jan;53(1):36-44. (IF: 6.0) (14 ISI-citations)
56. Hilbrands R, Hurman VA, Gillard P, Velthuis JH, De Waele M, Mathieu C, Kaufman L, Pipeleers-Marichal M, Ling Z, Movahedi B, Jacobs-Tulleneers-Thevissen D, Monbaliu D, Ysebaert D, Gorus FK, Roep BO, Pipeleers DG, Keymeulen B. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. **Diabetes**. 2009 Oct;58(10):2267-76. (IF: 7.3) (55 ISI-citations) (Subject of editorial)
57. Gillard P, Hurman V, Van der Auwera B, Decallonne B, Poppe K, Roep BO, Gorus F, Mathieu C, Pipeleers D, Keymeulen B. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. **Diabetes Care**. 2009 Oct;32(10):1817-9. (IF: 13.4) (9 ISI-citations)
58. Vandemeulebroucke E, Gorus FK, Decochez K, Weets I, Keymeulen B, De Block C, Tits J, Pipeleers DG, Mathieu C; Belgian Diabetes Registry. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. **Diabetes Metab**. 2009 Sep;35(4):319-27. (IF: 3.7) (15 ISI-citations)
59. Philips JC, Keymeulen B, Mathieu C, Scheen AJ. Monoclonal antibodies in diabetes: almost approaching the dream?. **Rev Med Liege**. 2009 May-Jun;64(5-6):327-33. French. (2 ISI-citations)

60. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. **Lancet**. 2009 Jun 20;373(9681):2125-35. (IF: 53.3) (774 ISI-citations)
61. Bergman AJ, Cote J, Maes A, Zhao JJ, Roadcap BA, Sun L, Valesky RJ, Yang A, Keymeulen B, Mathijs Z, De Smet M, Laethem T, Davies MJ, Wagner JA, Herman GA. Effect of sitagliptin on the pharmacokinetics of simvastatin. **J Clin Pharmacol**. 2009 Apr;49(4):483-8. (IF: 2.9) (21 ISI-citations)
62. Roelen DL, Huurman VA, Hilbrands R, Gillard P, Duinkerken G, van der Meer-Prins PW, Versteeg-van der Voort Maarschalk MF, Mathieu C, Keymeulen B, Pipeleers DG, Roep BO, Claas FH. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. **Clin Exp Immunol**. 2009 Apr;156(1):141-8. (IF: 3.5) (29 ISI-citations)
63. Gillard P, Vandemeulebroucke E, Keymeulen B, Pirenne J, Maes B, De Pauw P Vanrenterghem Y, Pipeleers D, Mathieu C. Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients. **Transplantation**. 2009 Feb 15;87(3):402-7. (IF: 4.0) (15 ISI-citations)
64. Huurman VA, Velthuis JH, Hilbrands R, Tree TI, Gillard P, van der Meer-Prins PM, Duinkerken G, Pinkse GG, Keymeulen B, Roelen DL, Claas FH, Pipeleers DG, Roep BO. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. **Am J Transplant**. 2009 Feb;9(2):382-8. (IF: 6.5) (43 ISI-citations)
65. Pipeleers D, Chintinne M, Denys B, Martens G, Keymeulen B, Gorus F. Restoring a functional beta-cell mass in diabetes. **Diabetes Obes Metab**. 2008 Nov;10 Suppl 4:54-62. Review. (IF: 6.0) (29 ISI-citations)
66. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial. **Lancet**. 2008 Oct 18;372(9647):1385-93. (IF: 53.3) (282 ISI-citations)
67. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. **Lancet**. 2008 Oct 18;372(9647):1394-402. (IF: 53.3) (276 ISI-citations)
68. Keymeulen B. Therapies aimed at preservation or restoration of beta cell function in type 1 diabetes. **Verh K Acad Geneesk Belg**. 2008;70(2):85-103. Review.
69. Huurman VA, Hilbrands R, Pinkse GG, Gillard P, Duinkerken G, van de Linde P, van der Meer-Prins PM, Versteeg-van der Voort Maarschalk MF, Verbeeck K, Alizadeh BZ, Mathieu C, Gorus FK, Roelen DL, Claas FH, Keymeulen B, Pipeleers DG, Roep BO. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. **PLoS One**. 2008 Jun 18;3(6):e2435. (IF: 2.8) (118 ISI-citations)
70. Davies M, Lavallo-González F, Storms F, Gomis R; AT.LANTUS Study Group. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. **Diabetes Obes Metab**. 2008 May;10(5):387-99. (IF: 6.0) (36 ISI-citations)

71. Gillard P, Ling Z, Mathieu C, Crenier L, Lannoo M, Maes B, Roep B, Gorus F, Pipeleers D, Keymeulen B. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. **Transplantation**. 2008 Jan 27;85(2):256-63. (IF: 4.0) (24 ISI-citations)
72. Weets I, Rooman R, Coeckelberghs M, De Block C, Van Gaal L, Kaufman JM, Keymeulen B, Mathieu C, Weber E, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. The age at diagnosis of type 1 diabetes continues to decrease in Belgian boys but not in girls: a 15-year survey. **Diabetes Metab Res Rev**. 2007 Nov;23(8):637-43. (IF: 3.9) (12 ISI-citations)
73. Truyen I, De Grijse J, Van Schravendijk C, De Smet D, Decochez K, Vandemeulebroucke E, Giri M, Keymeulen B, Mathieu C, Van Gaal L, De Pauw P, Weets I, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. Adiponectin levels do not predict clinical onset of type 1 diabetes in antibody-positive relatives. **Diabetologia**. 2007 Oct;50(10):2143-6. (IF: 6.0) (6 ISI-citations)
74. Truyen I, De Grijse J, Weets I, Kaufman L, Pipeleers L, Nanos N, Decochez K, Hilbrands R, Kaufman JM, Keymeulen B, Mathieu C, Van Gaal L, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. Identification of prediabetes in first-degree relatives at intermediate risk of type 1 diabetes. **Clin Exp Immunol**. 2007 Aug;149(2):243-50. (IF: 3.5) (5 ISI-citations)
75. Keymeulen B, Gillard P, Mathieu C, Movahedi B, Maleux G, Delvaux G, Ysebaert D, Roep B, Vandemeulebroucke E, Marichal M, In 't Veld P, Bogdani M, Hendrieckx C, Gorus F, Ling Z, van Rood J, Pipeleers D. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. **Proc Natl Acad Sci U S A**. 2006 Nov 14;103(46):17444-9. (IF: 9.5) (107 ISI-citations)
76. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. **J Clin Endocrinol Metab**. 2006 Nov;91(11):4612-9. (IF: 5.8) (343 ISI-citations)
77. Keymeulen B. New therapies aimed at the preservation or restoration of beta cell function in type 1 diabetes. **Acta Clin Belg**. 2006 Sep-Oct;61(5):275-85. Review. (IF: 1.0) (2 ISI-citations)
78. Decochez K, Rippley RK, Miller JL, De Smet M, Yan KX, Matthijs Z, Riffel KA, Song H, Zhu H, Maynor HO, Tanaka W, Johnson-Levonas AO, Davies MJ, Gottesdiener KM, Keymeulen B, Wagner JA. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects. **Drugs R D**. 2006;7(2):99-110. (IF: 4.5) (5 ISI-citations)
79. Maleux G, Gillard P, Keymeulen B, Pipeleers D, Ling Z, Heye S, Thijs M, Mathieu C, Marchal G. Feasibility, safety, and efficacy of percutaneous transhepatic injection of beta-cell grafts. **J Vasc Interv Radiol**. 2005 Dec;16(12):1693-7. (IF: 2.8) (20 ISI-citations)
80. Keymeulen B, Pipeleers D, Chatenoud L. CD3-antibody therapy in new-onset type 1 diabetes mellitus. **N Engl J Med**. 2005 Dec 10 353(19): 2087-2087. (IF: 79.3)
81. Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA, Keymeulen B, Pipeleers D, Drijfhout JW, Roep BO. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. **Proc Natl Acad Sci U S A** 2005 Dec 20;102(51):18425-30. (IF: 9.5) (171 ISI-citations)

82. Van Kampen CA, van de Linde P, Duinkerken G, van Schip JJ, Roelen DL, Keymeulen B, Pipeleers DG, Claas FH, Roep BO. Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. **Transplantation**. 2005 Jul 15;80(1):118-26. (IF: 4.0) (21 ISI-citations)
83. Mathieu C, Keymeulen B. Prevention of type 1 diabetes: interventions in mice and in humans. **Rev Med Liege**. 2005 May-Jun;60(5-6):303-5. Review. French.
84. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. **N Engl J Med**. 2005 Jun 23;352(25):2598-608. (IF: 79.3) (720 ISI-citations) (Subject of editorial)
85. Decochez K, Truyen I, van der Auwera B, Weets I, Vandemeulebroucke E, de Leeuw IH, Keymeulen B, Mathieu C, Rottiers R, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. **Diabetologia**. 2005 Apr;48(4):687-94. (IF: 6.0) (36 ISI-citations)
86. Gillard P, Ling Z, Lannoo M, Maes B, Maleux G, Pipeleers D, Keymeulen B, Mathieu C. Beta-cell transplantation restores metabolic control and quality of life in a patient with subcutaneous insulin resistance. **Diabetes Care**. 2004 Sep;27(9):2243-4. (IF: 13.4) (7 ISI-citations)
87. Movahedi B, Keymeulen B, Lauwers MH, Goes E, Cools N, Delvaux G. Laparoscopic approach for human islet transplantation into a defined liver segment in type-1 diabetic patients. **Transpl Int**. 2003 Mar;16(3):186-90. (IF: 3.2) (22 ISI-citations)
88. Decochez K, De Leeuw IH, Keymeulen B, Mathieu C, Rottiers R, Weets I, Vandemeulebroucke E, Truyen I, Kaufman L, Schuit FC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. IA-2 autoantibodies predict impending type I diabetes in siblings of patients. **Diabetologia**. 2002 Dec;45(12):1658-66. (IF: 6.0) (50 ISI-citations)
89. Weets I, Siraux V, Daubresse JC, De Leeuw IH, Féry F, Keymeulen B, Krzentowski G, Letiexhe M, Mathieu C, Nobels F, Rottiers R, Scheen A, Van Gaal L, Schuit FC, Van der Auwera B, Rui M, De Pauw P, Kaufman L, Gorus FK; Belgian Diabetes Registry. Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood. **J Clin Endocrinol Metab**. 2002 Jun;87(6):2597-605. (IF: 5.8) (20 ISI-citations)
90. Weets I, De Leeuw IH, Du Caju MV, Rooman R, Keymeulen B, Mathieu C, Rottiers R, Daubresse JC, Rocour-Brumioul D, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. The incidence of type 1 diabetes in the age group 0-39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. **Diabetes Care**. 2002 May;25(5):840-6. (IF: 13.4) (81 ISI-citations)
91. Pipeleers D, Keymeulen B, Chatenoud L, Hendrieckx C, Ling Z, Mathieu C, Roep B, Ysebaert D. A view on beta cell transplantation in diabetes. **Ann N Y Acad Sci**. 2002 Apr;958:69-76. Review. (IF: 4.3) (25 ISI-citations)
92. Fisher AL, DePuy E, Shih T, Stearns R, Lee Y, Gottesdiener K, Flattery S, De Smet M, Keymeulen B, Musson DG. Liquid chromatographic-tandem mass spectrometric urine assay for a highly metabolized cyclic ureidobenzenesulfonamide: issues concerning assay specificity and quality control preparation. **J Pharm Biomed Anal**. 2001 Dec;26(5-6):739-52. (IF: 2.8) (13 ISI-citations)

93. Li R, Keymeulen B, Gerlo E. Determination of glycerol in plasma by an automated enzymatic spectrophotometric procedure. **Clin Chem Lab Med.** 2001 Jan;39(1):20-4. (IF: 3.6) (9 ISI-citations)
94. Weets I, Van Autreve J, Van der Auwera BJ, Schuit FC, Du Caju MV, Decochez K, De Leeuw IH, Keymeulen B, Mathieu C, Rottiers R, Dorchy H, Quartier E, Gorus FK; Belgian Diabetes Registry. Male-to-female excess in diabetes diagnosed in early adulthood is not specific for the immune-mediated form nor is it HLA-DQ restricted: possible relation to increased body mass index. **Diabetologia.** 2001 Jan;44(1):40-7. (IF: 6.0) (52 ISI-citations)
95. Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, Lens S, Porras AG, Dieck J, Keymeulen B, Gertz BJ. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. **Clin Pharmacol Ther.** 2000 Dec;68(6):626-36. (IF: 0.9) (46 ISI-citations)
96. Decochez K, Keymeulen B, Somers G, Dorchy H, De Leeuw IH, Mathieu C, Rottiers R, Winnock F, ver Elst K, Weets I, Kaufman L, Pipeleers DG, Rottiers R; Belgian Diabetes Registry. Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. **Diabetes Care.** 2000 Aug;23(8):1072-8. (IF: 13.4) (35 ISI-citations)
97. Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, Pipeleers D, De Vries RR, Glass FH, Roep BO. Tolerance to kidney allograft transplanted into Type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismatches. **Diabetologia.** 1999 Nov;42(11):1379-80. (IF: 6.0) (13 ISI-citations)
98. Bex M, Buyschaert M, De Leeuw I, De Schepper J, Fery F, Hermans MP, Keymeulen B, Lauvaux JP, Letiexhe M, Mathieu C, Nobels FR, Rottiers R, Scheen A, Schmitt H, Van Crombrugge P, Van Gaal L. Insulin lispro (Humalog) in the treatment of diabetes mellitus: overview of belgian clinical data from global studies. **Acta Clin Belg.** 1999 Oct;54(5):241-5. Review. (IF: 1.0) (1 ISI-citation)
99. Lee Y, Conroy JA, Stepanavage ME, Mendel CM, Somers G, McLoughlin DA, Olah TV, De Smet M, Keymeulen B, Rogers JD. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. **Br J Clin Pharmacol.** 1999 Apr;47(4):373-8. (IF: 3.8) (30 ISI-citations)
100. Roep BO, Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, Pipeleers D, Claas FH, de Vries RR. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. **Diabetes.** 1999 Mar;48(3):484-90. (IF: 7.3) (134 ISI-citations)
101. Weytjens C, Keymeulen B, Van Haleweyn C, Somers G, Bossuyt A. Rapid gastric emptying of a liquid meal in long-term Type 2 diabetes mellitus. **Diabet Med.** 1998 Dec;15(12):1022-7. (IF: 3.1) (26 ISI-citations)
102. Gorus F, Dorchy H, Keymeulen B, Vandewalle C, Decochez K, Weets I, Winnock F. Type 1 diabetes mellitus: is this heterogeneous autoimmune diseases predictable, preventable, curable? **Annales de pediatrie.** 1998 Oct; 45(8): 530-42 (IF:0.1)
103. Keymeulen B, Ling Z, Gorus FK, Delvaux G, Bouwens L, Gruppig A, Hendrieckx C, Pipeleers-Marichal M, Van Schravendijk C, Salmela K, Pipeleers DG. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. **Diabetologia.** 1998 Apr;41(4):452-9. (IF: 6.0) (127 ISI-citations)

104. Gorus FK, Vandewalle CL, Winnock F, Lebleu F, Keymeulen B, Van der Auwera B, Falorni A, Dorchy H, Féry F, Pipeleers DG. Increased prevalence of abnormal immunoglobulin M, G, and A concentrations at clinical onset of insulin-dependent diabetes mellitus: a registry-based study. The Belgian Diabetes Registry. **Pancreas**. 1998 Jan;16(1):50-9. (IF: 3.0) (10 ISI-citations)
105. Keymeulen B, Anselmo J, Pipeleers D. Length of metabolic normalization after rat islet cell transplantation depends on endocrine cell composition of graft and on donor age. **Diabetologia**. 1997 Oct;40(10):1152-8. (IF: 6.0) (20 ISI-citations)
106. Vandewalle CL, Falorni A, Lernmark A, Goubert P, Dorchy H, Keymeulen B et al. Associations of GAD65- and IA-2-autoantibodies with genetic risk markers in new-onset IDDM patients and their siblings. **Diabetes Care** 1997 Oct;20 (10): 1547-1552. (IF: 13.4) (67 ISI-citations)
107. Van Der Auwera BJ, Vandewalle CL, Schuit FC, Winnock F, De Leeuw IH, Van Imschoot S, Lamberigts G, Gorus F, Balasse E, Becq H, Beirinck J, Claeys L, Coeckelberghs M, Coolens JL, Coucke W, Couturier E, Craen R, Daubresse JC, De Schepper J, Delvigne C, Dorchy H, Du Caju M, Fery F, Gaham M, Gerard J, Gillet C, Guiot J, Herbaut c, Keymeulen B, Krzentowski G, Letiexhe M, Monballyu J, Moorkens G, Nicolaij D, Nobels F, Pelckmans MC, Purnode A, Rooman R, Rottiers R, Scheen A, Schutyser J, Sodoyez JC, Somers G, Terriere L, Teuwen J, Tits J, Van Acker K, Van Crombrugge P, Van Gaal L, Vandebussche E, Vanneste S, Vercammen C, Vertommen J. CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. **Clin exp Immunol**. 1997; 110(1): 98-103 (IF:3.5) (89 ISI-citations)
108. Gorus FK, Goubert P, Semakula C, Keymeulen B, et al. IA-2-autoantibodies complement GAD(65)-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. **Diabetologia** 1997 Jan; 40 (1): 95-99. (IF: 6.0) (127 ISI-citations)
109. Keymeulen B, Korbitt G, De Paepe M, Gorus F, Klöppel G, Pipeleers DG. Long-term metabolic control by rat islet grafts depends on the composition of the implant. **Diabetes**. 1996 Dec;45(12):1814-21. (IF: 7.3) (33 ISI-citations)
110. Keymeulen B, de Metz K, Cluydts R, Bossuyt A, Somers G. Technetium-99m hexamethylpropylene amine oxime single-photon emission tomography of regional cerebral blood flow in insulin-dependent diabetes. **Eur J Nucl Med**. 1996 Feb;23(2):163-8. (IF: 3.5) (17 ISI-citations)
111. Myrsén U, Keymeulen B, Pipeleers DG, Sundler F. Beta cells are important for islet innervation: evidence from purified rat islet-cell grafts. **Diabetologia**. 1996 Jan;39(1):54-9. (IF: 6.0) (20 ISI-citations)
112. Verstraeten E, Cluydts R, Keymeulen B, Somers G. The impact of induced hypoglycemia on neuropsychological performance in diabetic patients; **Int J Psychol**. 1996; 31(3-4): 35426. (IF:1.9)
113. Keymeulen B, Bossuyt A, Peeters TL, Somers G. 111In-octreotide scintigraphy: a tool to select patients with endocrine pancreatic tumors for octreotide treatment? **Ann Nucl Med**. 1995 Aug;9(3):149-52.
114. De Paepe ME, Keymeulen B, Pipeleers D, Klöppel G. Proliferation and hypertrophy of liver cells surrounding islet grafts in diabetic recipient rats. **Hepatology**. 1995 Apr;21(4):1144-53. (IF: 14.1) (25 ISI-citations)

115. Keymeulen B, Jacobs A, de Metz K, de Sadeleer C, Bossuyt A, Somers G. Regional cerebral hypoperfusion in long-term type 1 (insulin-dependent) diabetic patients: relation to hypoglycaemic events. **Nucl Med Commun.** 1995 Jan;16(1):10-6. (IF: 1.5) (32 ISI-citations)
116. De Vits A, Keymeulen B, Bossuyt A, Somers G, Verbruggen LA. Progressive diaphyseal dysplasia (Camurati-Engelmann's disease). Improvement of clinical signs and of bone scintigraphy during pregnancy. **Clin Nucl Med.** 1994 Feb;19(2):104-7. (IF: 6.3) (5 ISI-citations)
117. Keymeulen B, Somers G, Naessens A, Verbruggen LA. False positive ELISA serologic test for Lyme borreliosis in patients with connective tissue diseases. **Clin Rheumatol.** 1993 Dec;12(4):526-8. (IF: 2.1) (6 ISI-citations)
118. Jacobs A, Keymeulen B, Eeckhout E, de Geeter F, Somers G, Bossuyt A. Semiquantitative analysis of cerebral blood flow by means of 99Tcm-HMPAO SPECT in individuals before and after a high altitude Himalayan expedition. **Nucl Med Commun.** 1993 Aug;14(8):702-5. (IF: 1.5) (8 ISI-citations)
119. Keymeulen B, Vetri M, Gorus F, Vanbrabant B, Pipeleers DG. The effect of insulin treatment on function of intraportally grafted islets in streptozotocin-diabetic rats. **Transplantation.** 1993 Jul;56(1):60-4. (IF: 4.0) (23 ISI-citations)
120. Gorus FK, Anselmo J, Keymeulen B. Type 1 (insulin-dependent) diabetes mellitus: an autoimmune, predictable and preventable disease? Lessons from national registries and new challenges to clinical biology. **Acta Clin Belg.** 1993;48(2):96-108. Review. (IF: 1.0) (9 ISI-citations)
121. Keymeulen B, Somers G. Immunointervention in type 1 (insulin-dependent) diabetes mellitus. **Acta Clin Belg.** 1993;48(2):86-95. Review. (IF: 1.0) (2 ISI-citations)
122. Hubloue I, Keymeulen B, Delvaux G, Somers G. Hepatic artery aneurysm. Case reports with review of the literature. **Acta Clin Belg.** 1993;48(4):246-52. (IF: 1.0) (7 ISI-citations)
123. Somers G, Keymeulen B, Segers O. Some thoughts on the treatment of non-insulin-dependent diabetes mellitus. **Acta Clin Belg.** 1993;48(4):221-7. Review. (IF: 1.0)
124. Gorus FK, Sodoyez JC, Pipeleers DG, Keymeulen B, Foriers A, Van Schravendijk CF. Detection of autoantibodies against islet amyloid polypeptide in human serum. Lack of association with type 1 (insulin-dependent) diabetes mellitus, or with conditions favouring amyloid deposition in islets. The Belgian Diabetes Registry. **Diabetologia.** 1992 Nov;35(11):1080-6. (IF: 6.0) (22 ISI-citations)
125. Keymeulen B, Teng H, Vetri M, Gorus F, In't Veld P, Pipeleers DG. Effect of donor islet mass on metabolic normalization in streptozotocin-diabetic rats. **Diabetologia.** 1992 Aug;35(8):719-24. (IF: 6.0) (32 ISI-citations)
126. Van Erps J, Schmedding E, Naessens A, Keymeulen B. Kingella kingae, a rare cause of bacterial meningitis. **Clin Neurol Neurosurg.** 1992;94(2):173-5. (IF: 1.7) (11 ISI-citations)